抗体薬物複合体(ADC)の世界市場:シアトルジェネティクス技術、ImmunoGen技術、Immunomedics技術...市場調査レポートについてご紹介

【英文タイトル】Global Antibody Conjugates Drugs Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview of ADCs
• Antibodies
• Evolution of mAb therapeutics
• Conjugated mAbs
• History
• Key components in ADCs
• Next-generation ADCs
• Advantages
• Challenges
• Outsourcing of ADCs manufacturing
• Emergence of ADCs
• Current marketed ADCs

PART 06: Pipeline portfolio
• Information on pipeline candidates

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by MOA
• IgG1 antibodies
• HER2 antibodies

PART 09: Market segmentation by technologies used in ADCs
• Seattle Genetics (SGEN) technology
• ImmunoGen (IMGN) technology
• Immunomedics (IMMU) technology

PART 10: Geographical segmentation

PART 11: Market drivers
• Robust late-stage pipeline
• Rising prevalence of cancers
• Increase in demand for antibody conjugates
• Reimbursement policies

PART 12: Impact of drivers

PART 13: Market challenges
• High developmental costs
• Stringent regulations
• Risk of side effects

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Strategic alliances
• Increased outsourcing of drug development
• Emergence of targeted and combination therapies

PART 16: Vendor landscape
• Competitive scenario
• Key news
• F. Hoffmann-La Roche
• Seattle Genetics
• Takeda Pharmaceuticals

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Comparison of small molecule and mAbs
Exhibit 03: Preparation of mAbs
Exhibit 04: Timeline of ADCs
Exhibit 05: Key components
Exhibit 06: Components of next-generation ADCs
Exhibit 07: Advantages of ADCs
Exhibit 08: Emergence of ADCs
Exhibit 09: Marked ADCs products
Exhibit 10: Pipeline portfolio of ADCs
Exhibit 11: Pipeline share of ADCs
Exhibit 12: Market share of ADCs in clinical development
Exhibit 13: Few target antigens for ADCs in clinical development
Exhibit 14: Top five companies share in ADC pipeline
Exhibit 15: Global ADCs market 2015-2020 ($ billions)
Exhibit 16: Five forces analysis
Exhibit 17: Global ADCs market segmentation by MOA
Exhibit 18: Components in IMGN technology
Exhibit 19: Share of ADCs technologies
Exhibit 20: Global ADCs market by geography 2015
Exhibit 21: ADCs market in Americas 2015
Exhibit 22: ADCs market in Europe 2015
Exhibit 23: ADCs market in Japan 2015
Exhibit 24: Global incidence of cancer 2015 and 2020
Exhibit 25: Impact of drivers
Exhibit 26: Impact of drivers and challenges
Exhibit 27: F. Hoffmann-La Roche: Pharmaceutical division segmentation by revenue 2015
Exhibit 28: F. Hoffmann-La Roche: ADC segmentation by revenue 2015
Exhibit 29: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 30: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla by revenue 2015
Exhibit 31: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in US 2013-2015 ($ millions)
Exhibit 32: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Europe 2014 and 2015 ($ millions)
Exhibit 33: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Japan 2014-2015 ($ millions)
Exhibit 34: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in ROW 2013-2015 ($ millions)
Exhibit 35: F. Hoffmann La-Roche: Kadcyla pipeline products
Exhibit 36: F. Hoffmann La-Roche: Key takeaways
Exhibit 37: Seattle Genetics: YoY revenue and growth rate of ADCETRIS in US and Canada ($ millions)
Exhibit 38: Seattle Genetics: ADCETRIS developmental pipeline
Exhibit 39: Seattle Genetics: ADCs pipeline and seven clinical trial programs
Exhibit 40: Seattle Genetics: ADC collaborations
Exhibit 41: Seattle Genetics: Key takeaways
Exhibit 42: Takeda: Business segmentation by revenue 2015
Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2015
Exhibit 44: Takeda Pharmaceuticals: YoY growth and revenue generated from ADCETRIS (except US and Canada) 2013-2015 ($ millions)
Exhibit 45: Takeda Pharmaceuticals: Key takeaways


【レポート販売概要】

■ タイトル:抗体薬物複合体(ADC)の世界市場:シアトルジェネティクス技術、ImmunoGen技術、Immunomedics技術
■ 英文:Global Antibody Conjugates Drugs Market 2016-2020
■ 発行日:2016年3月31日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8911
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。